Races of small molecule clinical trials for the treatment of COVID‐19: An up‐to‐date comprehensive review.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 16, doi. 10.1002/ddr.21895
- By:
- Publication type:
- Article
Works matching IS 02724391 AND DT 2022 AND VI 83 AND IP 1
Results: 19
1
2
Medicinal chemistry of pyrophosphate mimics: A mini review.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 3, doi. 10.1002/ddr.21877
- By:
- Publication type:
- Article
3
ORY‐1001, a KDM1A inhibitor, inhibits proliferation, and promotes apoptosis of triple negative breast cancer cells by inactivating androgen receptor.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 208, doi. 10.1002/ddr.21860
- By:
- Publication type:
- Article
4
Chrysin modulates protein kinase IKKε/TBK1, insulin sensitivity and hepatic fatty infiltration in diet‐induced obese mice.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 194, doi. 10.1002/ddr.21859
- By:
- Publication type:
- Article
5
Potential of nafimidone derivatives against co‐morbidities of epilepsy: In vitro, in vivo, and in silico investigations.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 184, doi. 10.1002/ddr.21858
- By:
- Publication type:
- Article
6
The PD‐1/PD‐L1 binding inhibitor BMS‐202 suppresses the synthesis and secretion of gonadotropins and enhances apoptosis via p38 MAPK signaling pathway.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 176, doi. 10.1002/ddr.21857
- By:
- Publication type:
- Article
7
Targeting TRAF3IP2 alleviates high glucose‐induced cardiomyocyte inflammation and apoptosis.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 167, doi. 10.1002/ddr.21856
- By:
- Publication type:
- Article
8
TSPAN1 silencing protects against cerulein‐induced pancreatic acinar cell injury via targeting AGR2.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 158, doi. 10.1002/ddr.21855
- By:
- Publication type:
- Article
9
Loganin exerts a protective effect on ischemia–reperfusion‐induced acute kidney injury by regulating JAK2/STAT3 and Nrf2/HO‐1 signaling pathways.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 150, doi. 10.1002/ddr.21853
- By:
- Publication type:
- Article
10
Sodium Danshensu inhibits the progression of lung cancer by regulating PI3K/Akt signaling pathway.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 88, doi. 10.1002/ddr.21846
- By:
- Publication type:
- Article
11
Antibacterial and anti‐inflammatory activity of valproic acid‐pyrazole conjugates as a potential agent against periodontitis.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 131, doi. 10.1002/ddr.21851
- By:
- Publication type:
- Article
12
Xanthatin inhibits human colon cancer cells progression via mTOR signaling mediated energy metabolism alteration.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 119, doi. 10.1002/ddr.21850
- By:
- Publication type:
- Article
13
Comprehensive investigations for a potential natural prophylaxis—A cellular and murine model for apple cider vinegar against hydrogen peroxide and scopolamine induced oxidative stress.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 105, doi. 10.1002/ddr.21849
- By:
- Publication type:
- Article
14
Effects of notoginsenoside R1 on attenuating depressive behavior induced by chronic stress in rats through induction of PI3K/AKT/NF‐κB pathway.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 97, doi. 10.1002/ddr.21847
- By:
- Publication type:
- Article
15
Overexpression of ARHI increases the sensitivity of cervical cancer cells to paclitaxel through inducing apoptosis and autophagy.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 142, doi. 10.1002/ddr.21852
- By:
- Publication type:
- Article
16
Circ_0001667 knockdown blocks cancer progression and attenuates adriamycin resistance by depleting NCOA3 via releasing miR‐4458 in breast cancer.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 75, doi. 10.1002/ddr.21845
- By:
- Publication type:
- Article
17
PMEPA1 interference activates PTEN/PI3K/AKT, thereby inhibiting the proliferation, invasion and migration of pancreatic cancer cells and enhancing the sensitivity to gemcitabine and cisplatin.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 64, doi. 10.1002/ddr.21844
- By:
- Publication type:
- Article
18
Synthesis and evaluation of 2‐(4‐[4‐acetylpiperazine‐1‐carbonyl] phenyl)‐1H‐benzo[d]imidazole‐4‐carboxamide derivatives as potential PARP‐1 inhibitors and preliminary study on structure‐activity relationship
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 55, doi. 10.1002/ddr.21843
- By:
- Publication type:
- Article
19
Issue Information.
- Published in:
- Drug Development Research, 2022, v. 83, n. 1, p. 1, doi. 10.1002/ddr.21823
- Publication type:
- Article